Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 17/20 | 0.56 |
| ▸ | GUCY1B1 | Q02153 | 17/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL516290 | 0.88 | GUCY1A1 (0.51) | GUCY1A1GUCY1B1KCNH2ADORA3TTK | |
| Formic Acid SCHEMBL516509 | 0.80 | TTK (0.43) | GUCY1A1GUCY1B1KCNH2TTK | |
| SCHEMBL7903452 | 0.78 | GUCY1A1 (0.50) | GUCY1A1GUCY1B1KCNH2TTK | |
| SCHEMBL516656 | 0.78 | TTK (0.47) | GUCY1A1GUCY1B1KCNH2TTK | |
| SCHEMBL516244 | 0.73 | RAB9A (0.48) | GUCY1A1GUCY1B1KCNH2TTK | |
| SCHEMBL516733 | 0.69 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL14549794 | 0.69 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL14549800 | 0.67 | GUCY1A1 (1.00) | GUCY1A1GUCY1B1KCNH2ADORA3 | |
| SCHEMBL516306 | 0.67 | GUCY1A1 (0.52) | GUCY1A1GUCY1B1KCNH2 | |
| SCHEMBL12323244 | 0.64 | GUCY1A1 (0.85) | GUCY1A1GUCY1B1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER IP GMBH (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029002-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | GUCY1A1 3203/4885GUCY1B1 2537/4885KCNH2 302/4885 |
| US-20130303559-A1 | BENZIMIDAZOLE AND PYRAZOLOPYRIDINE DERIVATIVES FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASES | PKM, BRD3, TNNI3 | GUCY1A1 3203/4885GUCY1B1 2537/4885KCNH2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.